To evaluate bioactive and total IGF-I levels in healthy and GH-treated children and adolescents, emphasizing the establishment of pediatric reference ranges.
Key Findings:
Bioactive IGF-I increased with age and correlated positively with total IGF-I and IGF-I/IGFBP-3, with implications for GH therapy.
13% of GH-treated patients had bioactive IGF-I above +2SD, while 25% had total IGF-I above +2SD, indicating potential concerns.
Bioactive IGF-I was within reference ranges for most GH-treated children.
Interpretation:
Monitoring bioactive IGF-I may help optimize GH dosing, especially in specific patient subgroups where total IGF-I may not be an appropriate efficacy marker.
Limitations:
Limited follow-up period for assessing long-term risks of GH therapy, and potential biases in the study population.
Conclusion:
Bioactive IGF-I levels provide valuable insights for managing GH therapy in pediatric patients, particularly in non-GHD conditions, emphasizing the need for careful monitoring.
by Lea Vilmann, Jakob Albrethsen, Jørgen Holm Petersen, Stine Agergaard Holmboe, Peter Christiansen, Katharina Maria Main, Line Cleemann, Kristian Horsman Hansen, Jan Frystyk, Casper P Hagen, Anders Juul
